×
About 790 results

ALLMedicine™ Anaplastic Thyroid Carcinoma Center

Research & Reviews  295 results

Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiti...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236774
Disease Markers; Hou X, Chen C et. al.

Jul 1st, 2022 - Thyroid cancer (THCA) represents a frequently seen endocrine cancer, which can be divided as anaplastic thyroid carcinoma (ATC), follicular thyroid carcinoma (FTC), and papillary thyroid carcinoma (PTC). A total of 362 IDEGs were obtained from TCG...

HSA-MnO2-131I Combined Imaging and Treatment of Anaplastic Thyroid Carcinoma.
https://doi.org/10.1177/15330338221106557
Technology in Cancer Research & Treatment; Yan Z, Zhang X et. al.

Jun 16th, 2022 - Purpose Compelling evidence suggests that nanoparticles (NPs) play a crucial role in cancer therapy. NPs templated with human serum albumin (HSA) has good retention in tumors. Manganese dioxide (MnO2) has been used to enhance the effect of radioth...

Retraction to: miR-199a-5p suppresses epithelial- mesenchymal-transition in anaplastic ...
https://doi.org/10.3233/CBM-229002
Cancer Biomarkers : Section A of Disease Markers;

Jun 14th, 2022 - Retraction to: miR-199a-5p suppresses epithelial- mesenchymal-transition in anaplastic thyroid carcinoma cells via targeting Snail signals.|2022||

Papillary Thyroid Carcinoma
https://emedicine.medscape.com/article/282276-overview

Jun 14th, 2022 - Practice Essentials Papillary thyroid carcinoma (PTC) is the most common form of well-differentiated thyroid cancer, and the most common form of thyroid cancer to result from exposure to radiation. Papillary carcinoma appears as an irregular solid...

Papillary Thyroid Carcinoma
http://emedicine.medscape.com/article/282276-overview

Jun 14th, 2022 - Practice Essentials Papillary thyroid carcinoma (PTC) is the most common form of well-differentiated thyroid cancer, and the most common form of thyroid cancer to result from exposure to radiation. Papillary carcinoma appears as an irregular solid...

see more →

Guidelines  3 results

The revised clinical practice guidelines on the management of thyroid tumors by the Jap...
https://doi.org/10.1507/endocrj.EJ20-0025
Endocrine Journal; Ito Y, Onoda N et. al.

Apr 10th, 2020 - The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the ther...

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
https://doi.org/10.6004/jnccn.2018.0089
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Nasr C et. al.

Dec 14th, 2018 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summa...

Anaplastic Thyroid Carcinoma, Version 2.2015.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986600
Journal of the National Comprehensive Cancer Network : JN... Haddad RI, Lydiatt WM et. al.

Sep 12th, 2015 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosage...

see more →

Clinicaltrials.gov  5 results

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT04592484

May 20th, 2022 - This is a first-in-human, Phase 1/2 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of CDK-002 in subjects with advanced/metastatic, recurrent, injectable solid tumors, whose disease has progressed despite receiving...

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT03181100

Aug 12th, 2020 - PRIMARY OBJECTIVE: I. To determine if targeted therapy + atezolizumab (cohorts 1-3) will lead to improved overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). SECONDARY OBJECTIVES: I. To evaluate the safety and efficacy (Resp...

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
https://clinicaltrials.gov/ct2/show/NCT02114658

Aug 3rd, 2017 - The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT00507429

Jun 9th, 2014 - Anaplastic thyroid carcinoma (ATC) is a high-grade neoplasm, characterized by an aggressive clinical course with brief survival, and refractoriness to currently available local and systemic modalities of treatment. There is no standard therapy for...

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
https://clinicaltrials.gov/ct2/show/NCT00115739

Apr 21st, 2014 - Anaplastic thyroid carcinomas (ATC) are high grade neoplasms, which account for approximately 2% to 5% of primary malignant thyroid tumors but more than 50% of thyroid cancer deaths. Because therapies for anaplastic thyroid carcinoma are very limi...

see more →

News  13 results

Running, a Lot of Discipline, and a Little Bit of Jazz: Walter J. Curran Jr Is a Giant of Cancer Care in Radiation Oncology
https://www.onclive.com/view/running-a-lot-of-discipline-and-a-little-bit-of-jazz-walter-j-curran-jr-is-a-giant-of-cancer-care-in-radiation-oncology

Apr 6th, 2022 - Walter J. Curran Jr, MD, started a new job this year working for an Australia-based oncology services provider, so it’s no surprise that he spent the summer with his mind and his device screens tethered to the other side of the world. Then again,...

Next-Generation BRAF Inhibitor Plus Cobicistat Elicits Encouraging Activity in BRAF+ Refractory Solid Tumors
https://www.onclive.com/view/next-generation-braf-inhibitor-cobicistat-elicits-encouraging-activity-in-braf-refractory-solid-tumors

Oct 6th, 2021 - PLX8394, a next-generation BRAF inhibitor, in combination with cobicistat (Tybost) was found to demonstrate encouraging clinical activity with an acceptable safety profile in patients with BRAF-mutated, refractory solid tumors, according to result...

Advanced HCC: What's Next?
https://www.onclive.com/view/advanced-hcc-whats-next

Apr 2nd, 2021 - Transcript: Ghassan K. Abou-Alfa, MD: I would like to end our very valuable discussion here by asking each one of you about—all right, great, out of nothing we moved in the speed of light. I’m not sure even if there is any other disease that w...

Priority Review Designation in TGCT, BLA Submitted in HER2+ Breast Cancer, and More
https://www.onclive.com/view/priority-review-designation-in-tgct-bla-submitted-in-her2-breast-cancer-and-more

Apr 2nd, 2021 - Today- A priority review designation in tenosynovial giant cell tumor, a biologic license application submitted in HER2-positive breast cancer, a recommendation in renal cell carcinoma, encouraging findings in prostate cancer and multiple myelo...

Targeted Treatment Tied to Longer Survival in Patients With Anaplastic Thyroid Cancer
https://www.staging.medscape.com/viewarticle/936044

Aug 21st, 2020 - NEW YORK (Reuters Health) - With the introduction of targeted treatments for anaplastic thyroid carcinoma, patients have seen significant improvements in survival, according to a new report. "Over the last 5 years, a greater understanding of the m...

see more →